About
Cleerly is a comprehensive, AI-enabled web-based platform designed to transform how clinicians detect and manage coronary artery disease (CAD). By analyzing coronary CT angiography (CCTA) data through advanced machine learning, Cleerly quantifies atherosclerosis with precision—measuring plaque volume, composition, length, and location across the entire coronary tree. The platform offers three core products: Cleerly Plaque Analysis for detailed plaque characterization, Cleerly ISCHEMIA for non-invasive determination of likely ischemia presence or absence, and Cleerly COMPARE for longitudinal tracking of disease progression over time. Cleerly ISCHEMIA has demonstrated superior diagnostic accuracy over competing non-invasive tests such as FFRCT and stress testing in prospective multicenter clinical trials, including CREDENCE and PACIFIC. Cleerly is built for healthcare providers, payors, and health systems seeking to improve cardiac care workflows. By reducing the need for additional downstream testing, it can lower costs while enhancing diagnostic confidence. With commercial insurance coverage expanding and Category I CPT code support, Cleerly integrates seamlessly into clinical and billing workflows. Coronary artery disease accounts for over 900,000 deaths annually in the US. Cleerly's mission is to make early, accurate, and personalized cardiac risk assessment standard of care—helping clinicians act early before a heart attack occurs.
Key Features
- AI-Powered Plaque Analysis: Quantifies atherosclerosis by measuring plaque volume, composition, length, and location across all coronary vessels using machine learning.
- Cleerly ISCHEMIA: Non-invasive detection of likely ischemia presence or absence, shown in clinical trials to outperform FFRCT and stress testing in diagnostic accuracy.
- Stenosis Evaluation: Evaluates stenosis severity in both 2D (diameter and area) and 3D (lumen and vessel volume) for comprehensive coronary assessment.
- Cleerly COMPARE: Enables longitudinal tracking of plaque and disease progression over time to monitor treatment effectiveness.
- Clinical Workflow Integration: Supports Category I CPT code billing and commercial insurance coverage, integrating smoothly into existing clinical and payor workflows.
Use Cases
- Cardiologists using AI-analyzed CCTA reports to stratify patient risk and personalize heart attack prevention plans.
- Health systems integrating Cleerly into cardiac care pathways to reduce unnecessary invasive testing and lower diagnostic costs.
- Radiologists leveraging Cleerly's plaque quantification tools to deliver more detailed and actionable coronary artery disease reports.
- Payors collaborating with Cleerly to improve diagnostic accuracy and reduce costly downstream cardiac interventions.
- Clinical researchers using Cleerly's longitudinal tracking to study plaque progression and evaluate treatment effectiveness over time.
Pros
- Clinically Validated Accuracy: Proven in prospective multicenter trials (CREDENCE, PACIFIC) to outperform competing non-invasive ischemia tests including FFRCT and SPECT.
- Comprehensive Whole-Heart Assessment: Provides a detailed, quantifiable picture of coronary artery disease across the entire heart in a single non-invasive scan.
- Reduces Downstream Testing: By accurately identifying ischemia non-invasively, Cleerly can reduce the need for additional expensive or invasive diagnostic procedures.
- Insurance & Billing Support: Commercial insurance coverage and Category I CPT code support make reimbursement and clinical adoption more straightforward.
Cons
- Requires CCTA Imaging: The platform depends on coronary CT angiography scans, which require specialized imaging equipment and trained radiology staff.
- Enterprise-Focused Pricing: Designed for health systems and clinical practices; pricing and access are not publicly listed, making evaluation difficult for smaller providers.
- Limited to Cardiac Use Case: Cleerly is purpose-built for coronary artery disease and does not extend to other diagnostic or clinical domains.
Frequently Asked Questions
What is Cleerly and how does it work?
Cleerly is an AI-driven, web-based platform that analyzes coronary CT angiography (CCTA) scans to quantify plaque buildup, assess stenosis severity, and detect likely ischemia. It uses machine learning to deliver detailed, clinically actionable reports to help physicians personalize heart disease treatment.
Is Cleerly covered by insurance?
Yes, Cleerly has expanded commercial insurance coverage and supports Category I CPT code billing. Providers can use the Payor Policy Look-up Tool on the Cleerly website to check specific coverage.
How is Cleerly different from traditional stress testing?
Unlike stress tests, Cleerly provides a non-invasive, comprehensive assessment of plaque presence, composition, and ischemia. Clinical trials show Cleerly ISCHEMIA has higher diagnostic accuracy than stress testing and FFRCT in predicting ischemia and future cardiac events.
Who is Cleerly designed for?
Cleerly is designed for healthcare providers, cardiologists, radiologists, health systems, and payors who want more accurate, actionable cardiac risk assessments to improve patient outcomes and streamline diagnostic workflows.
What products does Cleerly offer?
Cleerly offers three main products: Cleerly Plaque Analysis (detailed plaque characterization), Cleerly ISCHEMIA (non-invasive ischemia detection), and Cleerly COMPARE (longitudinal disease tracking over time).
